Article Text

Download PDFPDF

SAT0608-HPR EULAR POINTS TO CONSIDER FOR THE DETECTION, ASSESSMENT AND MANAGEMENT OF NON-ADHERENCE IN PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES
Free
  1. V. Ritschl1,
  2. T. Stamm1,
  3. D. Aletaha1,
  4. J. W. Bijlsma2,
  5. P. Boehm3,
  6. R. Dragoi4,
  7. E. Dures5,
  8. F. Estévez-López6,
  9. L. Gossec7,
  10. A. Iagnocco8,
  11. M. Nudel9,
  12. A. Marques10,
  13. E. Moholt11,
  14. B. Van den Bemt12,13,
  15. K. Viktil14,
  16. M. Voshaar15,
  17. A. De Thurah16,17,
  18. L. Carmona18
  1. 1Medical University of Vienna, Vienna, Austria
  2. 2University Medical Center Utrecht, Utrecht, Netherlands
  3. 3Deutsche Rheuma-Liga Bundesverband e.V., Bonn, Germany
  4. 4”Victor Babes” University of Medicine and Pharmacy, Timișoara, Romania
  5. 5University of the West of England, Bristol, United Kingdom
  6. 6Erasmus University Medical Center, Rotterdam, Netherlands
  7. 7Sorbonne Université, Paris, France
  8. 8Università degli Studi di Torino, Turin, Italy
  9. 9Mifrakim Tz’eirim, Haifa, Israel
  10. 10Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
  11. 11Diakonhjemmet Hospital, Oslo, Norway
  12. 12Sint Maartenskliniek, Nijmegen, Netherlands
  13. 13Radboud Univiersity Medical Center, Nijmegen, Netherlands
  14. 14Diakonhjemmet Hospital Pharmacy, Oslo, Norway
  15. 15University of Twente, Enschede, Netherlands
  16. 16Aarhus University Hospital, Aarhus, Denmark
  17. 17Aarhus University, Aarhus, Denmark
  18. 18InMusc, Madrid, Spain

Abstract

Background: Non-adherence to medication and non-pharmacological interventions precludes reaching an optimal outcome. 30 to 80% of patients with rheumatic and musculoskeletal diseases (RMDs) do not adhere to their recommended treatment regimens.

Objectives: The objective of this EULAR task force was to establish recommendations/points to consider (PtC) for the detection, assessment and management of non-adherence in people with RMDs.

Methods: A EULAR task force (TF) was established, and the EULAR standardised operating procedures for the development of PtCs were followed. The TF included rheumatologists, health professionals in rheumatology (HPRs), and patient-representatives from 12 countries. A systematic literature review of reviews was conducted in advance to support the TF in formulating the PtC. Agreement was obtained by Delphi technique in three rounds (0-10 rating scale).

Results: A definition of adherence, 4 overarching principles and 9 PtC were formulated (table).

Conclusion: The PtCs can help health-care providers to support people with RMDs to adhere to the agreed treatment plan.

Table.

Overarching principles and points to consider.

Disclosure of Interests: Valentin Ritschl: None declared, Tanja Stamm Grant/research support from: AbbVie, Roche, Consultant of: AbbVie, Sanofi Genzyme, Speakers bureau: AbbVie, Roche, Sanofi, Daniel Aletaha Grant/research support from: AbbVie, Novartis, Roche, Consultant of: AbbVie, Amgen, Celgene, Lilly, Medac, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi Genzyme, Speakers bureau: AbbVie, Celgene, Lilly, Merck, Novartis, Pfizer, Sanofi Genzyme, UCB, Johannes WJ Bijlsma Grant/research support from: Roche, Speakers bureau: Roche, Lilly, Peter Boehm: None declared, Razvan Dragoi Speakers bureau: MSD, AbbVie, Novartis, Roche, Pfizer, Myllan, Sandoz, Emma Dures Grant/research support from: Independent Learning Grant from Pfizer, combined funding for a research fellow from Celgene, Abbvie and Novartis, Paid instructor for: A fee from Novartis to deliver training to nurses., Fernando Estévez-López: None declared, Laure Gossec Grant/research support from: Lilly, Mylan, Pfizer, Sandoz, Consultant of: AbbVie, Amgen, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis, UCB, Annamaria Iagnocco Grant/research support from: Abbvie, MSD and Alfasigma, Consultant of: AbbVie, Abiogen, Alfasigma, Biogen, BMS, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Sanofi and Sanofi Genzyme, Speakers bureau: AbbVie, Alfasigma, BMS, Eli-Lilly, Janssen, MSD, Novartis, Sanofi, Michal Nudel: None declared, Andrea Marques: None declared, Ellen Moholt: None declared, Bart van den Bemt Grant/research support from: UCB, Pfizer and Abbvie, Consultant of: Delivered consultancy work for UCB, Novartis and Pfizer, Speakers bureau: Pfizer, AbbVie, UCB, Biogen and Sandoz., Kirsten Viktil: None declared, Marieke Voshaar Grant/research support from: part of phd research, Speakers bureau: conducting a workshop (Pfizer), Annette de Thurah Grant/research support from: Novartis (not relevant for the present study)., Speakers bureau: Lily (not relevant for the present study)., Loreto Carmona Grant/research support from: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gebro Pharma, SA (All trhough institution)

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.